Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Tremfya — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Biogen logo
BIIBTECFIDERA — Total Revenue
$109.5M-46.9%
Biogen logo
BIIBFAMPYRA — Total Revenue
$0-100%
Biogen logo
BIIBTecfidera — Revenue
$2.48B+1.9%
Vertex Pharmaceuticals logo
VRTXTRIKAFTA/KAFTRIO — Product revenues, net
$2.35B-7.1%
Biogen logo
BIIBTYSABRI — Total Revenue
$441.5M+15.7%
Vertex Pharmaceuticals logo
VRTXALYFTREK — Product revenues, net
$424.4M+687%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's tremfya — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's tremfya — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported tremfya — sales to customers (note 9) of $1.61B in Q1 2026.
How has Johnson & Johnson's tremfya — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's tremfya — sales to customers (note 9) increased by 68.2% year-over-year, from $956M to $1.61B.
What is the long-term trend for Johnson & Johnson's tremfya — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's tremfya — sales to customers (note 9) has grown at a 24.8% compound annual growth rate (CAGR), from $2.13B to $5.16B.
What does tremfya — sales to customers (note 9) mean?
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line within the company's immunology portfolio. It reflects the market demand and commercial adoption of this therapeutic agent among healthcare providers and patients. Monitoring this figure helps investors assess the product's contribution to overall segment growth and its competitive positioning in the specialty medicine market.